Evidence map›Paper›PMID 24846288›Full record

ArticlePloS one2014

Immunization of rabbits with highly purified, soluble, trimeric human immunodeficiency virus type 1 envelope glycoprotein induces a vigorous B cell response and broadly cross-reactive neutralization.

Gerald V Quinnan, Olusegun Onabajo, Pengfei Zhang, Lianying Yan, Joseph J Mattapallil, Zhiqiang Zhang, Ming Dong, Min Lu, David Montefiori, Celia LaBranche and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Gerald V QuinnanDepartment of Preventive Medicine and Biometrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America.
Olusegun OnabajoDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America.
Pengfei ZhangDepartment of Preventive Medicine and Biometrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America.
Lianying YanDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America.
Joseph J MattapallilDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America.
Zhiqiang ZhangDepartment of Preventive Medicine and Biometrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America.
Ming DongDepartment of Preventive Medicine and Biometrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America.
Min LuDepartment of Microbiology and Molecular Genetics, Public Health Research Institute, New Jersey Medical School, Newark, New Jersey, United States of America.
David MontefioriDepartment of Surgery, Duke University Medical Center, Durham, North Carolina, United States of America.
Celia LaBrancheDepartment of Surgery, Duke University Medical Center, Durham, North Carolina, United States of America.
Christopher C BroderDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America.
Uniformed Services University of the Health Sciences · USDuke Medical Center · US

Funding

High Potency HIV-1 Broadly Cross-Reactive NeutralizationU01AI078412 · NIAID · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI QUINNAN, GERALD V. · 2008 to 2012
$2.9M
NIAID NIH HHS AI078412NIAID NIH HHS U01 AI078412
6 · The paper itself

Abstract

Previously we described induction of cross-reactive HIV-1 neutralizing antibody responses in rabbits using a soluble HIV-1 gp140 envelope glycoprotein (Env) in an adjuvant containing monophosphoryl lipid A (MPL) and QS21 (AS02A). Here, we compared different forms of the same HIV-1 strain R2 Env for antigenic and biophysical characteristics, and in rabbits characterized the extent of B cell induction for specific antibody expression and secretion and neutralizing responses. The forms of this Env that were produced in and purified from stably transformed 293T cells included a primarily dimeric gp140, a trimeric gp140 appended to a GCN4 trimerization domain (gp140-GCN4), gp140-GCN4 with a 15 amino acid flexible linker between the gp120 and gp41 ectodomain (gp140-GCN4-L), also trimeric, and a gp140 with the flexible linker purified from cell culture supernatants as either dimer (gp140-L(D)) or monomer (gp140-L(M)). Multimeric states of the Env proteins were assessed by native gel electrophoresis and analytical ultracentrifugation. The different forms of gp140 bound broadly cross-reactive neutralizing (BCN) human monoclonal antibodies (mAbs) similarly in ELISA and immunoprecipitation assays. All Envs bound CD4i mAbs in the presence and absence of sCD4, as reported for the R2 Env. Weak neutralization of some strains of HIV-1 was seen after two additional doses in AS02A. Rabbits that were given a seventh dose of gp140-GCN4-L developed BCN responses that were weak to moderate, similar to our previous report. The specificity of these responses did not appear similar to that of any of the known BCN human mAbs. Induction of spleen B cell and plasma cells producing immunoglobulins that bound trimeric gp140-GCN4-L was vigorous, based on ELISpot and flow cytometry analyses. The results demonstrate that highly purified gp140-GCN4-L trimer in adjuvant elicits BCN responses in rabbits accompanied by vigorous B cell induction.

Indexed as

ImmunizationAdjuvants, ImmunologicAnimalsAntibodies, NeutralizingAntibody FormationB-LymphocytesCross Reactionsenv Gene Products, Human Immunodeficiency VirusEpitopes, B-LymphocyteHIV AntibodiesHIV AntigensHumansLymph NodesNeutralization TestsProtein BindingProtein MultimerizationAdjuvants, ImmunologicAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusEpitopes, B-Lymphocytegp140 envelope protein, Human immunodeficiency virus 1HIV AntibodiesHIV AntigensReceptors, CCR5

Identifiers

PMID24846288
PMCPMC4028264
OpenAlexW2043667904

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.